Page 93«..1020..92939495..»

You are currently browsing the Nano Medicine category

Cognis: Innovating for modern nutrition – turning expertise into food products

§ December 21st, 2010 § Filed under Nano Medicine Comments Off on Cognis: Innovating for modern nutrition – turning expertise into food products

From initial consumer insights to finished products, specialty chemicals supplier Cognis takes a systematic and holistic approach to innovation. The company’s Nutrition & Health strategic business unit utilizes all its specialist knowledge and expertise to create nutrition products that make people feel good, and help manufacturers to strengthen their brands. With its “Newtrition – Eat.Feel.Live.” concept, Cognis has developed its own wellness-based model for aligning products and solutions with market trends. Cognis’ weight management ingredient Tonalin® CLA is a prime example of this strategy in action.

skitched-20101202-113418.jpg
Cognis follows an open approach
to innovation that always
starts with the consumer

Any successful innovation starts with consumers – their needs, wants and expectations of the products they buy. That’s why innovation is about much more than just discovering new molecules. It is about identifying and anticipating market needs, then meeting them with targeted solutions that offer real benefits for the user, and the prospect of commercial success for customers.

The key trends of today: wellness and sustainability

These days, people’s desire for improved quality of life goes hand in hand with an increased environmental awareness. On the one hand, well-being, responsibility, and peace of mind are all values that are shaping consumer behavior, while on the other, increasingly stringent regulations are also forcing manufacturers to offer more sustainable products. With its well-established strategy of serving the markets driven by this wellness and sustainability megatrend, specialty chemicals supplier Cognis is extremely attuned to the lifestyle demands of modern consumers. As a result, sustainability and innovation at Cognis are inseparably linked, and its expertise in natural-source specialty chemicals is enabling customers to offer ever greener and better products. To strengthen this commitment to sustainability, the company adopted the internationally recognized 24 Principles of Green Chemistry and Green Engineering as a framework for all its product and process development activities.

The overall strategy: an open approach to innovation

Cognis has an innovation strategy that is built around four key principles: consumer insights, a holistic approach, generating value, and leading green technology. Sharing ideas and expertise as widely as possible allows promising innovations to be generated and developed faster and more effectively. All areas of the company – from R&D to production, and from sales and marketing to supply chain management – are actively involved in turning these ideas into innovations and bringing them rapidly to market. And this open approach to innovation even extends beyond the company, as cooperation with external partners also plays a big part.

Under Cognis’ market-focused approach, the innovation process typically starts with an analysis of market trends and user needs. For example, in 2009 a survey was carried out to discover what kinds of foods and supplements consumers would prefer for maintaining brain health. Based on the findings of this survey, Cognis is currently in the process of establishing a new brain health platform and developing innovative, marketable brain health products for use in functional foods and dietary supplements.

Cognis also works closely with many of its customers in targeted joint development projects, and leverages the opportunities offered by working with suppliers, universities and scientific research institutes all over the world. For example, an exclusive partnership with InterMed Discovery GmbH gives Cognis access to one of the world’s largest databases of natural products and IMD’s Bioprofiling® technology platform, providing the basis for a constant stream of innovative active ingredients for food applications. Cognis also looks for small and mid-size companies that have great ideas, but lack the means to bring these to market. With its scientific, formulation, regulatory, sales and marketing expertise, Cognis can provide the resources necessary to commercialize these ideas successfully, by acquiring either the intellectual property rights or the whole company. This open innovation approach allows Cognis and its customers to stay one step ahead of technological and business developments.

skitched-20101202-113449.jpg
A framework for product development and marketing: “Newtrition – Eat.Feel.Live.”

skitched-20101202-113523.jpg
The four aspects of wellness
that underpin the
“Newtrition - Eat.Feel.Live.” strategy

To provide a framework for generating new ideas for nutrition ingredients aligned with market demands, Cognis Nutrition & Health has developed the “Newtrition – Eat.Feel.Live.” strategy. By helping consumers to feel good, these products strengthen and differentiate the brands of the Cognis customers who use them. The strategy is based on improving service to manufacturers by understanding what consumers want – an approach that can be summarized as “Think B2C, act B2B”. Every Cognis nutritional ingredient is designed taking up to four dimensions of wellness into consideration – emotional perception, taste sensation, effect and convenience – thereby turning customers’ products into a well-being experience for the consumer.

An important market: weight management

The “Newtrition – Eat.Feel.Live.” strategy involves Cognis focusing on six areas of health: heart health, body composition, cognitive performance, immunity, and beauty from inside. As has been widely reported in recent years, overweight is now a major issue in many parts of the world, and so there is a global and growing market for body fat reduction and body composition management products. Consumers are seeking effective and lasting ways to control their weight in line with their healthy lifestyle aspirations, and this is driving growth and innovation in the functional food and food supplement markets.

Putting innovation into practice: Tonalin® CLA

A prime example of Cognis’ innovation strategy in action is Tonalin® CLA, an ingredient that can help to reduce body fat and preserve lean body mass, providing several health and wellness benefits. The Tonalin® success story began in 2002, when Cognis became aware of Natural ASA, an interesting start-up company in Norway doing R&D on conjugated linoleic acid (CLA). In February 2003, Cognis exclusively licensed ASA’s intellectual property (IP), technology, marketing rights and the Tonalin® trademark. Using this as a starting point, Cognis then developed its own IP relating to specifications, production processes and applications. Drawing on over 40 years of experience in lipid technology, Cognis was able to scale up production of the ingredient from small batches in the laboratory to a commercial manufacturing process. Cognis now transforms linoleic acid derived from natural safflower oil into CLA using a patented process that guarantees superior quality and ensures a high content of the essential bioactive substance. The entire process is compliant with current Good Manufacturing Practices (Food GMP) guidelines. A proprietary deodorization technology gives Tonalin® its superior sensory profile by removing all traces of odor and flavor. As a result, food manufacturers can buy the refined ingredient in a ready-to-use state being sure that adding Tonalin® won’t affect their food products’ taste. Today, Tonalin® is the market, quality, and innovation leader, and a recognized premium brand.

Benefits of Tonalin® CLA: proven efficacy

With 18 clinical studies published in peer review journals, Tonalin® is the most researched and tested CLA on the market. Clinical studies have demonstrated that CLA can help to reduce body fat by up to 20 percent (depending on the level of physical activity practiced by the subject) while maintaining or even increasing lean body mass, and preventing a yo-yo effect. It can also help to prevent age-related muscle loss. With these proven body-shaping effects, Tonalin® is ideal for products with claims like “Beauty from within”.

skitched-20101202-113614.jpg
The NaturLinea range is the first
range of food products in Europe
to use CLA as an active ingredient

Tonalin® CLA has already been in use as a dietary supplement for a decade. Cognis also has over six years’ experience of helping customers to launch successful functional food products containing CLA, more than any other company. Tonalin® CLA is currently used in numerous dietary supplements and food products worldwide. Spanish dairy company CAPSA (Corporación Alimentaria Peasanta) was the first manufacturer in the Western world to launch food products with added CLA in 2004 under its brandname NaturLínea con Tonalin.

The product range includes skimmed milk, yogurts and yogurt drinks. In 2008, Cognis started marketing Tonalin® CLA in the US as a food ingredient, after it was granted FDA GRAS (generally recognized as safe) status for applications including milk and flavored milk products, yogurt products, fruit juice products, soy milk beverages, meal replacement beverages and bars. Cognis is also the first company to achieve novel food approval for a CLA product in China. As a result, Tonalin CLA can now be used in a wider range of functional foods and beverages in the Chinese market. And finally, Cognis is currently in the process of obtaining novel food approval for Tonalin CLA in Europe. This is expected to be granted later this year – and when it is, it will revolutionize the market.

skitched-20101202-113706.jpg
Tonalin® CLA can be easily
incorporated e.g. in milk and
flavored milk products,
yogurt and yogurt drinks,
fruit juice products,
soy milk beverages,
meal replacement beverages
and bars and coffee specialties

Conclusion

Innovation involves much more than inventing new products. It also means looking for new application areas and having a clear understanding of regulations. To successfully meet the demands of sophisticated modern consumers, food manufacturers will need the scientific and regulatory expertise to create products with enhanced functionality, taste, texture and appearance. With over ten years’ experience in functional food products, and market-leading expertise in ingredients, formulations, applications and regulatory compliance, Cognis can provide food manufacturers with these resources. It works with companies around the globe to develop customized solutions that are effective, convenient, great-tasting – and include an added feel-good factor.

skitched-20101202-113748.jpg
Johannes Crotogino

Head of Innovation & New ingredients, Cognis GmbH

skitched-20101202-113839.jpg
Dr. Arne Ptock

Global Product Line Manager, Tonalin, Cognis GmbH

Read the Rest...

DKSH: Barley Balance Beta-Glucan

§ December 21st, 2010 § Filed under Nano Medicine Comments Off on DKSH: Barley Balance Beta-Glucan

Cereal Beta-Glucans from barley and oats are widely associated with an array of healthy benefits, most notably for heart health. Barley and oat have earned official Health Claims in the U.S. and have a similar claim pending in Europe for cholesterol lowering effect. Barley Beta-Glucans have been shown to be potent biological response modifiers affecting multiple systems often associated with chronic health issues. They are especially well suited to the growing trend of products that combine strong consumer appeal, with advanced nutritional profiles and proven health benefits. Barley Balance® is highly enriched in Beta-Glucan, all natural, minimally processed, and is easy to incorporate in a wide range of foods and beverages.

Barley Balance® Beta-Glucans have solid record in clinical trials for both traditional and emerging health benefits. The success shown in trials to reduce blood lipids, key risk factors in heart disease has been reconfirmed by recent studies. Strong evidence has emerged regarding their ability of these Beta-Glucans to modulate blood sugar and glycemic cycles. Recently new scientific evidence has established a direct link between the fermentation of barley Beta-Glucans and the release of hormones that suppress appetite (satiety). This is an important finding for advancing weight control via the diet.

This article is available in full in the Autumn 2010 issue of Nutraceuticals Now

Read the Rest...

Neptune: What you should know about Krill oil

§ December 21st, 2010 § Filed under Nano Medicine Comments Off on Neptune: What you should know about Krill oil

Neptune Technologies & Bioressources Inc. (Neptune) is the pioneer and has always been worldwide leader of the Omega-3 Krill Oil market. In fact, Neptune has single handedly created this market ever since its inception more than a decade ago. Neptune Krill Oil (NKO®) is a whole lipid oil extract of Antarctic krill (Euphausia Superba), a shrimp-like creature inhabiting cold waters of the ocean. Antarctic krill have a life span of about 5 to 10 years and are considered to be a keystone species.

NKO® is distinct from every other marine oil due to the fact that the omega-3 fatty acids, EPA and DHA, are attached to and carried by phospholipids. Phospholipids are a major component of all biological membranes and contribute to the membrane’s permeability and fluidity. Due to their amphipathic nature, having both lipid soluble and water soluble, phospholipids act as superior delivery systems. Most phospholipids in NKO® also contain choline, a small amine known as a component of the neurotransmitter acetylcholine. By weight, NKO® is comprised of at least 30% EPA and DHA and 40% phospholipids. Most of the EPA and DHA in NKO® are structurally intermingled with phospholipid molecules mimicking the way these nutrients occur naturally in cell membranes. In addition, NKO® contains a powerful antioxidant known as astaxanthin which has been shown to be up to 300 times more powerful than Vitamin E. The market has experienced a great increase in consumer awareness about Omega-3 and more recently this awareness has been directed towards the added health benefits from consuming omega-3 from krill oil. To this date NKO® remains to be the only krill oil with clinically proven human health benefits in cardiovascular, cognitive, joints and women’s health.

This article is available in full in the Autumn 2010 issue of Nutraceuticals Now

Read the Rest...

Forward to Autumn 2010 Issue

§ December 21st, 2010 § Filed under Nano Medicine Comments Off on Forward to Autumn 2010 Issue

Nutraceuticals are food or components of food which provide health benefits beyond basic nutrition including the prevention and treatment of diseases. There has been an increase in life expectancy of individuals and this trend is likely to continue globally. In parallel to this modern day life styles are associated with growing levels of stress, poor eating habits, lack of exercise and these have contributed to an increase in chronic disorders such as obesity, cardiovascular disease, diabetes, digestive disorders etc.

Obesity is directly related to an accelerated onset of diabetes and cardiovascular disease. The World Health Organisation (WHO) predicts that there will be more than 1.5 billion obese people globally by 2015. The UK has the highest percentage of obese adults (62.2%), followed by Germany and Spain where over 50% of the population is overweight. Cardiovascular disease (CVD) which includes myocardial infarction (heart attack), hypertension (high blood pressure), hypercholesterolaemia (high cholesterol) and cerebrovascular disease (stroke) is the number one cause of death in developed countries. Many factors pre-dispose to CVD including poor diet. The European population is aging fast and will challenge the resources of health care providers. The WHO estimates that about 16.6 million people around the globe die of CVD each year and the prediction is that this may rise to 11.1 million by 2020. As far as digestive health is concerned it is estimated that currently 1.0 million people in France, Germany, Italy, Spain and UK are suffering from Irritable Bowel Syndrome. Another issue linked to this is the growing prevalence of food allergies.

This is also placing a huge financial burden on health care providers and many governments are urging the public to take care of their individual health and improve their life style especially by changing their diet.

Nutraceuticals should be able to contribute to the prevention of the chronic diseases mentioned above and there are many players emerging in this area and they all contribute to the health and wellness market. All these organisations have to address three key issues of technology (1) establishment of scientific assessment standard for prevention of diseases (2) establishment of assessment system for disease prevention by human trials and (3) establishment of seamless system to transfer stage from basic research to industrialisation. Consumers are seeking novel food products which can enhance their health and factors currently influencing the growth of the nutraceutical sector include regulatory issues, consumer opinions, and the need for more conclusive research into new and novel ingredients.

The issue of regulation is an important one for all concerned. Within the European Union there are two categories of claims on foods: nutrition claims and health claims. The nutrition claims deal with content claims and comparative claims whilst the health claims deal with functional claims based on generally accepted scientific data and on newly developed scientific data. It’s likely that regulatory issues have put financial pressures on some nutraceutical companies and this may have led to a slowing down of the introduction of novel products. However, the regulatory issues also provide a new window for marketing and promoting nutraceuticals especially those directed at chronic diseases associated with age. The companies need to comply with the legislation and have a unique opportunity to work with government agencies and health providing organisations such that the nutraceuticals can be effectively marketed and directed at those who will benefit the most. To achieve this the companies need to significantly invest in research and development, advertising and promotional activities and effectively communicate the benefits of nutraceuticals to the consumers staying within the legislative boundaries and this will be linked to ethical marketing which the consumers are also seeking. In times of hard economic realities nutraceuticals have a role to play in maintaining health of the general population thus contributing to the savings in health care costs. This is the key to success in the European and worldwide nutraceuticals market.

Professor Khalid Rahman
Professor of Physiological Biochemistry Liverpool John Moores University.

Read the Rest...

Two new initiatives from the CSCC

§ December 21st, 2010 § Filed under Nano Medicine Comments Off on Two new initiatives from the CSCC

The Cancer Stem Cell Consortium (CSCC) has announced the launch of two new initiatives for 2011-2012. Information about these initiatives is available via the websites of the CSCC and Genome Canada.

The two initiatives are:

1. C4Resource: The Canada-California Collaborative Cancer Stem Cell Resource and Technology Platform Network or C4Resource, which would coordinate cancer stem cell research resources and platform technologies more efficiently and effectively to advance research and discovery and accelerate clinical translation of new findings; and,

2. Partnership with CIRM: A second funding partnership with the California Institute for Regenerative Medicine (CIRM) through the CIRM's Disease Team Therapy Development Research Awards.

Information about the CIRM Disease Team Therapy Development Research Award RFA is available at: http://www.cirm.ca.gov/RFA_10-05

Read the Rest...

International Stem Cell Corporation Announces Start of Marketing Collaboration with John Mauldin for Skin Care Products

§ December 21st, 2010 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Announces Start of Marketing Collaboration with John Mauldin for Skin Care Products

OCEANSIDE, Calif.--(BUSINESS WIRE)--International Stem Cell Corporation (OTCBB:ISCO),http://www.internationalstemcell.com, announced today that it had launched the first phase of its previously announced joint marketing campaign with John Mauldin, the founder and Chairman of Millennium Wave Investments, to market Lifeline Skin Care’s (LSC) new topical skin care products to more than one million of Mauldin’s subscribers. This launch follows ISCO’s earlier successful release to its own investor base and to the general public through its website,http://www.lifelineskincare.com.

“Having seen a strong demand from our investors and followers, we have been working diligently to increase both our marketing and production capabilities. John Mauldin’s participation will support the continuation of our rapid progress”

Mauldin, a best-selling writer, author of a monthly investment newsletter, and recognized marketing expert, provides LSC with the skills and a platform to enable LSC to continue expanding its sales while keeping marketing cost per customer lower than would be possible with a traditional media campaign.

Lifeline Skin Care’s exclusive patent pending skin rejuvenation serums contain extracts from ISCO’s proprietary “parthenogenetic” stem cells created from unfertilized eggs. The stem cell extract was discovered during ISCO’s therapeutic research that revealed the extract’s potential applications in skin cell rejuvenation. Independent third party testing indicates that both the day and the night serums now being offered have significant positive effects on the look and feel of the skin.

“Having seen a strong demand from our investors and followers, we have been working diligently to increase both our marketing and production capabilities. John Mauldin’s participation will support the continuation of our rapid progress,” says Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.

John Mauldin adds, “I’m pleased to be involved with LSC and to help these truly revolutionary skin care products reach a broader audience. This new collaboration gives me the ability to offer these unique LSC products to my loyal client base.”

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed and is now marketing a line of skin care products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website,http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of planned products, anticipated sales growth for recently introduced products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

Read the Rest...

International Stem Cell Corporation Announces $25 Million Common Stock Financing Agreement

§ December 21st, 2010 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Announces $25 Million Common Stock Financing Agreement

International Stem Cell Corporation (OTCBB:ISCO),http://www.internationalstemcell.com, announced today that it had entered into an agreement with Aspire Capital Fund, LLC, to provide, at the Company's sole option, up to $25 million of equity capital over the next three years. As part of this transaction, Aspire purchased, upon execution of the agreement, 333,333 shares of ISCO Common Stock at a price of $1.50 per share, a 7% premium over Friday's closing price of $1.40 per share.

Pricing of future sales under the agreement will be determined each time the Company elects to sell shares to Aspire by a formula that is based on the actual sale prices of the Company's stock over the 12 days preceding each sale to Aspire. Thus, the Company will control the timing and amount of any sales of its Common Stock to Aspire, and will always know at the time it gives a notice of sale what the cost of that round of financing will be.

Aspire has no right to require any sales by the Company, but is obligated to make purchases as the Company directs in accordance with the purchase agreement, and the Company has the right to terminate the agreement at any time. The agreement does not restrict other financings by the Company. A more detailed description of the transaction agreements with Aspire is set forth in the Company's current report on Form 8-K, filed today with the U.S. Securities and Exchange Commission.

Ray Wood, Chief Financial Officer of ISCO, commented on the agreement, "This transaction is designed to provide both a source of working capital and maximum flexibility for the Company in determining the pricing and timing of any future financing it elects to use under this agreement. It provides us with access to capital that we believe will be adequate to fund our research activities for an extended period of time, but does not preclude us from pursuing additional financing during the term of the agreement. Because of the pricing flexibility this facility gives us, we believe that this agreement will provide both the lowest cost of capital currently available, plus maximum flexibility in meeting our future financing needs. If we don't need working capital or don't need as much as expected, we may elect not to use the facility. If we do need capital, it is available and we can choose when to obtain it."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent humanstem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryosand, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and has developed and is now marketing a line of skin care products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

ABOUT ASPIRE CAPITAL FUND, LLC

Aspire Capital Fund, LLC is an institutional investor based in Chicago,Illinois, with a fundamental investment approach. Aspire Capital invests in a wide range of companies and industries emphasizing life sciences, energy and technology.

FORWARD-LOOKING STATEMENTS

Statements pertaining to financing plans and capital needs, anticipatedtechnological developments and therapeutic applications, the potential benefits of opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "should," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update these forward-looking statements.

Key Words: Stem Cells, Biotechnology, Parthenogenesis

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman, 760-940-6383
kaldrich@intlstemcell.com
or
Ray Wood, CFO, 760-640-6383
rwood@intlstemcell.com

Read the Rest...

International Stem Cell Corporation Announces Commercial Sales to General Public of Its Breakthrough Stem Cell-Based Lines of Skin Care Products

§ December 1st, 2010 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Announces Commercial Sales to General Public of Its Breakthrough Stem Cell-Based Lines of Skin Care Products


International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that the first new topical skin care products of its subsidiary, Lifeline Skin Care, are now available to the general public within the United States at http://www.lifelineskincare.com. Lifeline Skin Care's first two products consist of a Defensive Day Moisture Serum and Recovery Night Moisture Serum. Previously, these breakthrough serums, containing extracts from "parthenogenetic" stem cells, were available only to individuals and organizations formerly identified and selected for their interest in innovative approaches to skin care.

According to Lifeline Skin Care CEO, Dr. Ruslan Semechkin, "Because the quality products Lifeline Skin Care offers are experiencing strong demand and the human stem cell extracts require innovative manufacturing processes, we chose to develop our sales channels gradually and incrementally. We are very pleased with the customer feedback from our first limited launch and are delighted to now be able to expand production and make the products available to the general public within the US."

Purchases that could previously be made only by phone, can now be made directly through the company's website,http://www.lifelineskincare.com. "Enabling electronic order processing though our website provides the benefit of both lowering our transaction costs and increasing our scalability, while simultaneously simplifying the ordering process for our customers," said ISCO VP, Dr. Simon Craw.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans and related support, the potential benefits of planned products, anticipated sales growth for recently introduced products, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

International Stem Cell Corporation

Kenneth C. Aldrich, Chairman

1-760-940-6383

kaldrich@intlstemcell.com

or

Lifeline Skin Care, Inc.

Ruslan Semechkin, PhD, President & CEO Vice President, ISCO

ras@intlstemcell.com

Read the Rest...

International Stem Cell Corporation Announces the Commercial Launch of Its Breakthrough Stem Cell-Based Line of Skin Care Products

§ December 1st, 2010 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Announces the Commercial Launch of Its Breakthrough Stem Cell-Based Line of Skin Care Products

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today the commercial launch of its innovative line of topical skin care products by the company's wholly-owned subsidiary, Lifeline Skin Care ™ (http://www.lifelineskincare.com). Containing extracts from human "parthenogenetic" stem cells (hpSC), the products were formulated by a team of ISCO's research scientists in collaboration with cosmetic formulation experts to create an advanced scientific approach to skin care. The patent pending serums, which come in separate formulations for day and night time use, have been safety tested by highly regarded, independent laboratories, and have been shown to promote anti-aging of the skin.

The initial launch of the serums is to a pre-existing list of interested parties. We expect that the products will be available to the general public via our online store http://www.lifelineskincare.com in the near future.

A key innovation in creating the Lifeline Skin Care™ serums was the encapsulation of the parthenogenetic stem cell extractsinto nanospheres, which not only protect the proteins, but substantially enhance the effectiveness of the serums. World renowned skin cream formulation experts assisted ISCO's scientists to create the finished products and ensure that the final serums deliver the most up-to-date advances in skin rejuvenation technology that also helps to prevent and repair damage caused by the environment.

According to Gregory S. Keller, MD, FACS (2007 Specialist of the Year in Facial Cosmetic Surgery in Strathmore's "Who's Who"): "These new day and night serums represent a huge step forward in anti-aging skin care products. Combining liposome-encapsulated proteins derived from ISCO's powerful new class human stem cells with a unique blend of anti-oxidants, vitamins and natural extracts, allowed Lifeline Skin Care to create highly effective stem cell-based serums that provide strong anti-aging benefits."

The new skin rejuvenation serums are based on the breakthrough discovery that certain proteins derived from ISCO's proprietary pluripotent human parthenogenetic stem cells are beneficial to the culture of human skin cells in the laboratory. ISCO, the world leader in human parthenogenetic stem cell technology, is studying this new class of stem cells, and has demonstrated their therapeutic potential in many fields of regenerative medicine. Human parthenogenetic stem cells are created from unfertilized human eggs and do not involve any harm to a viable human embryo, thus avoiding serious ethical questions that surround other areas of stem cell research. hpSC possess unique immune-matching attributes making them an excellent platform for the development of cellular therapies for large populations of individuals. As of today, ISCO has successfully derived ten hpSC lines. One of these lines carries the most common immune type found within the US population and can be immune-matched to an estimated 75 million people worldwide.

"The commercial launch of the new skin care products represents an important step in the execution of ISCO's strategy. The revenue generated from sales will help support the development of our therapeutic programs utilizing our unique and powerful class of human pluripotent stem cells," said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, product introduction plans, the potential benefits of planned products, collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care, anti-aging

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20101116005754r1&sid=14230&distro=ftp

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com

or
Lifeline Skin Care, Inc.
Ruslan Semechkin, PhD, President & CEO
Vice President, ISCO
ras@intlstemcell.com

Read the Rest...

Heightened Interest from the Medical Research Community and New Funding of International Stem Cell Corporation’s (ISCO) Therapeutic Research

§ November 7th, 2010 § Filed under Nano Medicine Comments Off on Heightened Interest from the Medical Research Community and New Funding of International Stem Cell Corporation’s (ISCO) Therapeutic Research

International Stem Cell Corporation (OTCBB: ISCO), http://www.internationalstemcell.com, announced today that the recent presentation entitled "Hepatocyte-like cells derived from patient-specific human parthenogenetic stem cells possess functions of mature human hepatocytes including P450 activity" has been identified as an "AASLD Presidential Poster of Distinction" in the Stem Cells session of The Liver Meeting, the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), in Boston, MA, one of the most prestigious annual medical and scientific conferences. The abstract of the presentation is published in the peer-reviewed supplement to Hepatology, volume 52, number 4 (SUPPL), Oct. 2010, pg 965A, the official journal of the AASLD.

ISCO's CEO Andrey Semechkin, Ph.D., said, "For our cell biologists to have received this award from the leading society in the U.S. focused on treating liver diseases, demonstrates the high caliber of research being carried out at ISCO, and that human parthenogenetic stem cells and their differentiated derivatives are becoming of greater interest to the medical research community as a potential source of therapeutically valuable cells."

ISCO also announced today the initiation of the first in a series of animal studies designed to demonstrate whether hepatocytes and their progenitors derived from the human parthenogenetic stem cells show any disease modifying activity in vivo.

Dr. Nikolay Turovets, ISCO's Director of Research and Therapeutic Development said, "ISCO's continued focus on therapeutic development is critical to show that hepatocytes derived from stem cells can reproduce missing liver function in a diseased organism. Our first series of experiments are designed to test the ability of our cells to engraft and survive in vivo. A second set of experiments will investigate the functional activity of successfully engrafted cells. Data from these studies will also be used to guide the development of future IND submissions."

In other research news, ISCO announced that a grant in which ISCO is a partner, was recently funded by the Qualified Therapeutic Discovery Project Grants Program created under the healthcare reform legislation enacted last March. The study is led by Paul H. Chen, M.D. to investigate healing after corneal surgery using ISCO's corneal epithelial cells developed by ISCO's wholly-owned subsidiary Lifeline Cell Technology. ISCO's cells, combined with a proprietary surgical device developed by Dr. Chen, may provide safer and better long term results than LASIK. By utilizing ISCO's human corneal cells, ISCO and Dr. Chen believe that cellular enhanced PRK could eventually replace LASIK for many of the hundreds of thousands of patients who require corrective eye surgery.

According to Dr. Chen, "This collaborative work with ISCO could lead to a safer and more effective treatment that hopefully will provide quicker visual recovery, less pain, and an improved refractive correction outcome."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as" could", "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, hepatocytes, liver disease

International Stem Cell Corporation
Jeffrey D. Janus
Sr. Vice President, Operations
1-760-940-6383
jjanus@intlstemcell.com
or
Nikolay Turovets, Ph.D.
Director of Research and Therapeutic Development
nturovets@intlstemcell.com

Read the Rest...

Notes from The Chairman Concerning ISCO Price Fluctuations

§ October 31st, 2010 § Filed under Nano Medicine Comments Off on Notes from The Chairman Concerning ISCO Price Fluctuations

As a matter of policy, we at ISCO refrain from commenting on movements in the price of our stock. However, events yesterday were so unusual and have resulted in so many questions, that I think it is our duty to our shareholders to tell you what we know.

As best we can determine, Patrick Cox, who has been and continues to be a strong supporter of our company, was required yesterday by his publisher to cease coverage of our stock and issue a sell recommendation because he has an equity interest in a company with which we do business that could have been perceived as a conflict of interest. That has resulted in numerous negative comments on investor message boards that referred to the sell recommendation without giving the background or a full explanation. As a result, I felt it was important that we put the day's events into proper context. The following are what I believe to be the relevant excerpts from Patrick's article:

As you know, I've been a huge promoter of International Stem Cell Corp.'s (OTCBB: ISCO) parthenogenic stem cell technology. I've not only told you about the company, but I appeared on John Mauldin's podcast show with ISCO board chairman Ken Aldrich about six months ago. Aldrich and Mauldin subsequently became friends and found that their organizations were a perfect fit for marketing ISCO's cosmeceutical skin care product.

John Mauldin asked me to be a part of that organization. We looked hard at Agora Financial's policies as well as applicable SEC regulations and concluded that there would be no conflict of interest because the position gave me no direct interest in ISCO or its stock price....

My publisher, however, has grown increasingly uncomfortable with this arrangement. The reason is not that Agora Financial believes that there would be an actual conflict of interest. Rather, it is that it might be perceived as one by some, in particular SEC lawyers....

My publisher's trading policy's aim, however, is to keep me purely objective and disinterested. This policy is debatable, but I respect it. My only option, therefore, is to issue a sell order or face the wrath of a disappointed spouse.

You can probably guess what that means. I'm going to have to issue a sell order.

Patrick followed that with a supplement, in which he said, in part,

Just to re-iterate, now that I've seen the price action from this afternoon's sell alert, I'm not parting with the shares of International Stem Cell Corp. (OTCBB: ISCO) because I believe they are a bad investment (my feelings, as you probably know, are quite the opposite)...ISCO still has the transformational potential that I've told you about. The only real change is that I won't be able to update you from here on out -- due to an over abundance of caution from my publisher.

Obviously, we can't know for certain if these articles caused the price movement yesterday, but we believe they were a major factor. Moreover, the comments and the response of investors to them are beyond our control, but we do want to reassure all interested parties that there is no information of which we are aware to justify the price fluctuation that occurred yesterday.

I hope this will prove helpful.

Sincerely,

Ken Aldrich

Chairman

FORWARD-LOOKING STATEMENTS:

Statements pertaining to anticipated developments, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Read the Rest...

International Stem Cell Corporation Announces Completion of Its First Manufacturing Run of Lifeline Skin Care’s Stem Cell-Based Skin Rejuvenation…

§ October 27th, 2010 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Announces Completion of Its First Manufacturing Run of Lifeline Skin Care’s Stem Cell-Based Skin Rejuvenation…

International Stem Cell Corporation Announces Completion of Its First Manufacturing Run of Lifeline Skin Care's Stem Cell-Based Skin Rejuvenation Products

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, announced today that its wholly-owned subsidiary, Lifeline Skin Care, Inc., in partnership with an experienced OTC drug licensed manufacturer of cosmetic products, successfully manufactured its first scaled-up lots of stem cell-based skin creams, confirming that these unique products can be made in larger batch quantities and continue to meet Lifeline's high quality standards. This marks an important milestone in proving that two new technologies, the derivation of human parthenogenetic stem cells, and the packaging and delivery of critical anti-aging ingredients, including those derived from stem cells, can be scaled-up into a level of production suitable to meet commercial levels of demand.

Lifeline Skin Care's product development scientists have combined human parthenogenetic stem cell technology with the latest discoveries in skin rejuvenation to create its unique day and night skin care creams. ISCO's scientists were the first to intentionally create human parthenogenetic stem cells from unfertilized human eggs, thus avoiding the ethical concerns of harming a viable human embryo. ISCO's therapeutic research team discovered that such cells had qualities that made them suitable for skin care products, thus leading to the formation of ISCO's wholly-owned subsidiary, Lifeline Skin Care. Valuable assistance from ISCO's other wholly-owned subsidiary, Lifeline Cell Technology, allowed the rapid transition and scale-up of a research-based discovery into a quality-controlled commercial product. Lifeline Cell Technology is staffed with experts in the manufacture and quality control of cell based products.

According to Dr. Ruslan Semechkin, CEO of Lifeline Skin Care, "Although it will be necessary to continue to develop new technologies to further scale-up the production of our new skin care products, this first successful manufacturing run proves that the team of ISCO's therapeutic research scientists, in combination with Lifeline Skin Care's product development expertise and Lifeline Cell Technology's manufacturing and quality control expertise, has the ability to quickly develop and commercialize new products using stem cell technologies."

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeline Skin Care, Inc.
Ruslan Semechkin, Ph.D., President & CEO
Vice President, International Stem Cell Corporation
ras@intlstemcell.com

Read the Rest...

International Stem Cell Corporation Announces Launch Plans for New Skin Care Products

§ October 17th, 2010 § Filed under Nano Medicine Comments Off on International Stem Cell Corporation Announces Launch Plans for New Skin Care Products

International Stem Cell Corporation (OTCBB:ISCO), http://www.internationalstemcell.com, and a new firm to be formed by John Mauldin announced today the formation of a new joint marketing venture to launch a line of skin care products developed by ISCO's wholly owned subsidiary, Lifeline Skin Care, Inc. ('LSC'). Mauldin, a significant marketing talent, is president of Millennium Wave Investments and author of an economic letter that goes to over 1.5 million readers.

Lifeline Skin Care's products have been in active development for well over a year and involve a unique high-technology, patent pending formulation for skin rejuvenation crèmes, developed using ISCO's proprietary 'parthenogenetic' stem cells that do not require the use of fertilized embryos. The product was discovered during ISCO's therapeutic stem cell research that revealed the stem cell's potential applications in skin cell rejuvenation. Part of the discovery included developing a way to surround the proteins from the stem cells with a nanovesicle allowing for extended shelf life and enhanced delivery of the product to the skin. Independent third party testing indicates that the crèmes (one for day and one for nighttime application) have significant positive effects on the look and feel of the skin.

'This represents an amazing leap forward in the combination of a variety of cutting edge technologies to yield products that have the potential to find significant consumer acceptance. The anti-aging market is extremely large, and Lifeline Skin Care is offering something completely new and different. We are excited about the prospects,' said Kenneth Aldrich, Chairman of ISCO.

Because the LSC products involve a unique extract from living parthenogenetic stem cells, rather than 'off the shelf' ingredients used by most skin care products, it takes additional time to manufacture the products. Building inventory in advance of demand is critical to avoid disappointing customers.

ISCO and LSC believe the collaboration with Mauldin will provide a much broader potential customer base and a much lower market cost per customer than the alternative marketing programs previously considered. As a result, LSC has revised its previously announced marketing launch plans to be certain that it will have adequate product on hand to meet initial demand.

The initial product offering will be to ISCO's own database of investors and followers, originally set to launch October and now scheduled for November to coordinate with Mauldin's timetable. That will be followed with an offering to Mauldin's extensive subscription base and to a select market of other potential purchasers.

Only after these initial offerings have been completed, involving a total of over 1.5 million potential customers, will more broad scale product offerings be made. 'This will enable us to measure probable future demand, assure our loyal investors and Mauldin's subscribers and affiliates that they will be able to purchase all the products they require while allowing LSC to build an inventory of the unique stem cell extract that is at the heart of this new product,' said Dr. Ruslan Semechkin, CEO of Lifeline Skin Care.

'We are extraordinarily excited to be able to offer LSC's products to our loyal client base in a way that assures they will be able to obtain the product they want, plus monthly refills as required, in spite of the fact that LSC's products are unique and require time and care by many people to bring to market,' said John Mauldin, founder and Chairman of Millennium. 'This is a truly revolutionary approach to skin care. Early test results are very promising and I am excited to be associated with a company of the scientific reputation of International Stem Cell Corporation and their world-renowned staff.'

ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB)

International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike most other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals of differing racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology, and is developing a line of cosmeceutical products via its subsidiary, Lifeline Skin Care. ISCO is advancing novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics have not. More information is available on ISCO's website, http://www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.

FORWARD-LOOKING STATEMENTS

Statements pertaining to anticipated developments and therapeutic applications, the potential benefits of collaborations, affiliations, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products and the management of collaborations, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.

Key Words: Stem cells, parthenogenesis, biotechnology, skin care

International Stem Cell Corporation
Kenneth C. Aldrich, Chairman
1-760-940-6383
kaldrich@intlstemcell.com
or
Lifeine Skin Care, Inc.
Ruslan Semechkin, Ph.D., President & CEO
Vice President, ISCO
ras@intlstemcell.com

Read the Rest...

Careers in cell therapy & regenerative medicine

§ October 11th, 2010 § Filed under Nano Medicine Comments Off on Careers in cell therapy & regenerative medicine


As you will see just below, this post falls under the category of a thinly veiled and somewhat shameless plug which I hope you'll tolerate if I'm transparent about it upfront and I add what may be a little useful commentary along the way.

I won't have to convince "regular" readers of this "irregular" blog that regenerative medicine is one of the fastest growing life science sectors.

Given the pace of the industry's growth, the amount of public money being "invested" in the sector, and the general enthusiasm that the science generates, it is no surprise that is increasingly an area of interest for those seeking a new career path.

One commonly held misconception is that career opportunities in the sector are limited largely to those in early-stage research.

While it is true that the industry is still in the nascent stages of commercial development compared to other more mature segments in the broader biopharmaceutical industry, careers in regenerative medicine span the full research and commercial spectrum from pre-clinical to clinical research in both academic and corporate settings, manufacturing, regulatory, quality, operations, logistics, finance, business development, marketing, sales, communications, and executive management.

As has been discussed here in the past, most analysts agree that in 2008 the industry passed the $1 billion mark in annual revenue generated from sale of approved therapeutic products falling under the regenerative medicine category (see here for more in-depth analysis).

Furthermore, most large multinational life science companies are now investing heavily into the sector on the promise that it will revolutionize healthcare in the coming decades.

I believe the 2008 decision by Pfizer to create a substantial new Regenerative Medicine division will be seen as a seminal turning point in corporate perspectives on the industry. Since that point most life sciences have begun investing in regenerative medicine strategies and the trend has even leaked outside of life science to companies such as Google Ventures which has informally identified regenerative medicine as one of their primary areas of interest when looking at companies in which to invest.

Most major universities have now created both academic and research programs dedicated to the emerging field of regenerative medicine such that there is a new class of graduates now emerging in both scientific and commercial disciplines with regenerative medicine as a primary focus.

However, one of the difficulties with finding a career in regenerative medicine is that it is comprised of what has heretofore been fairly discrete disciplines of stem cell biology, pharmaceutical sciences, biotechnology, tissue engineering, stem cell transplantation, device technologies, cell therapies, etc.

Furthermore, most recruiters and online job sites have very little experience or focus on the industry making recruiting difficult for positions in regenerative medicine companies or departments. The task is further complicated by the fact that the candidate pool is small and diversely spread over a multitude of disciplines, centers, and a multitude of small companies.

Finally there are only now emerging industry publications, organizations, online communities, and websites that truly represent the broad spectrum of regenerative medicine and that can be used as central resources for recruiting.

All this is why my partners and I saw the need for an online recruiting tool that really focused on regenerative medicine in a way that would support the industry's maturation. What we wanted to bring was a very simple solution that would create as much value as possible for those looking to recruit the right talent into their regenerative medicine efforts. This was the genesis behind RegenerativeMedicineJobs.com.

(here comes the shameless part....)

About RMJ

At RegenerativeMedicineJobs.com, we believe the growth trajectory of this industry requires a specialized, online recruiting system – one that is more than just a website for posting jobs but also plugged into the large and diverse network of associations, publications, and social media that serves this industry.

RegenerativeMedicineJobs.com is a specialized online job board focused on recruiting for positions in the rapidly growing field of regenerative medicine. The site is simple to use and focused in scope. But this is more than just another website.

RMJ has developed a sophisticated system designed to leverage our extensive network in RM to ensure every post gets maximum attention and attracts the best candidates.

Traffic is pulled to the site and job postings are pushed to a targeted audience by focused social media and marketing campaigns. This is the latest way to recruit for any position in a regenerative medicine department, division, or company. This is regenerative medicine recruiting with a focus.

RegenerativeMedicineJobs.com (RMJ) is a collaboration between CTG Consulting, Co. and Pencilneck Software, Co. The personnel behind this collaboration created Cell Therapy News, Cell Therapy Blog, the LinkedIn Cell Therapy Industry Group, and have produced over a dozen organizational or event-based websites in the cell therapy, stem cell, and regenerative medicine space.

The site has been designed to be simple and intuitive with only one goal in mind: to be the best online tool for recruiting personnel into positions in the regenerative medicine industry.

We don't offer resume posting, career advice, assistance building your CV, hand holding, shoulders to cry on, or job postings outside of regenmed. We believe in the value of specialization.

The site is a listing of regenerative medicine jobs (period). All types of jobs for all types of organizations but only regenmed job (period).

We have only one rule: the jobs posted must be for a position within the regenerative medicine space. We define regenerative medicine as anything involving cell therapy, stem cells as therapies or tools for discovery or toxicity testing, or non-cell based programs/products (e.g., small molecules, biologics, devices, etc) used to replace or regenerate cells, tissues, or organs to restore, repair, or establish normal function.

The site has a topical niche with no regional focus or bias. This is meant to be a global tool equally useful for a company or university in Poland, Taiwan, Brazil, the United States, etc.

The site is also meant to be useful for recruiting any positions scientific or commercial, business or technical, executive or laborer.

*

We hope you find it useful.

We hope it contributes to the industry's growth and maturation.

We hope you will provide us feedback on what we're doing well and what we can do better.



http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com
Read the Rest...

Insights into the stem cells of CML

§ October 11th, 2010 § Filed under Nano Medicine Comments Off on Insights into the stem cells of CML

Insights into the stem cells of chronic myeloid leukemia by I Sloma, X Jiang, A C Eaves and C J Eaves, Leukemia 2010(Sep 23). [Epub ahead of print][PubMed citation]. Abstract:

Chronic myeloid leukemia (CML) has long served as a paradigm for generating new insights into the cellular origin, pathogenesis and improved approaches to treating many types of human cancer. Early studies of the cellular phenotypes and genotypes represented in leukemic populations obtained from CML patients established the concept of an evolving clonal disorder originating in and initially sustained by a rare, multipotent, self-maintaining hematopoietic stem cell (HSC). More recent investigations continue to support this model, while also revealing new insights into the cellular and molecular mechanisms that explain how knowledge of CML stem cells and their early differentiating progeny can predict the differing and variable features of chronic phase and blast crisis. In particular, these emphasize the need for new agents that effectively and specifically target CML stem cells to produce non-toxic, but curative therapies that do not require lifelong treatments.

Read the Rest...

On the low frequency of tumor-initiating cells

§ October 11th, 2010 § Filed under Nano Medicine Comments Off on On the low frequency of tumor-initiating cells

Tumor-Initiating Cells Are Rare in Many Human Tumors by Kota Ishizawa and 16 co-authors, including Benjamin G Neel and William Matsui, Cell Stem Cell 2010(Sep 3); 7(3): 279-282. [FriendFeed entry][PubMed citation]. Abstract:

Tumor-initiating cells (TICs) are defined by their ability to form tumors after xenotransplantation in immunodeficient mice and appear to be relatively rare in most human cancers. Recent data in melanoma indicate that the frequency of TICs increases dramatically via more permissive xenotransplantation conditions, raising the possibility that the true frequency of TICs has been greatly underestimated in most human tumors. We compared the growth of human pancreatic, non-small cell lung, and head and neck carcinomas in NOD/SCID and NSG mice. Although TIC frequency was detected up to 10-fold higher in NSG mice, it remained low (<1 in 2500 cells) in all cases. Moreover, aldehyde dehydrogenase-positive (ALDH(+)) and CD44(+)CD24(+) cells, phenotypically distinct cells enriched in TICs, were equally tumorigenic in NOD/SCID and NSG mice. Our findings demonstrate that TICs are rare in these cancers and that the identification of TICs and their frequency in other human malignancies should be validated via primary tumors and highly permissive xenotransplantation conditions.

Read the Rest...

Must the last CML cell be killed?

§ October 11th, 2010 § Filed under Nano Medicine Comments Off on Must the last CML cell be killed?

Do we have to kill the last CML cell? DM Ross, TP Hughes and JV Melo, Leukemia 2010(Sep 16) [Epub ahead of print][FriendFeed entry][PubMed citation][Full text]. The abstract of this OA review:

Previous experience in the treatment of chronic myeloid leukaemic (CML) has shown that the achievement of clinical, morphological and cytogenetic remission does not indicate eradication of the disease. A complete molecular response (CMR; no detectable BCR-ABL mRNA) represents a deeper level of response, but even CMR is not a guarantee of elimination of the leukaemic, because the significance of CMR is determined by the detection limit of the assay that is used. Two studies of imatinib cessation in CMR are underway, cumulatively involving over 100 patients. The current estimated rate of stable CMR after stopping imatinib is approximately 40%, but the duration of follow-up is relatively short. The factors that determine relapse risk are yet to be identified. The intrinsic capacity of any residual leukaemic cells to proliferate following the withdrawal of treatment may be important, but there may also be a role for immunological suppression of the leukaemic clone. No currently available test can formally prove that the leukaemic clone is eradicated. Here we discuss the sensitive measurement of minimal residual disease, and speculate on the biology of BCR-ABL-positive cells that may persist after effective therapy of CML.

Read the Rest...

Critical molecular pathways in CSCs of CML

§ October 11th, 2010 § Filed under Nano Medicine Comments Off on Critical molecular pathways in CSCs of CML

Critical molecular pathways in cancer stem cells of chronic myeloid leukemia by Y Chen, C Peng, C Sullivan, D Li and S Li, Leukemia 2010(Sep); 24(9): 1545-54. Epub 2010 Jun 24. [Connotea bookmark][PubMed citation][Full text]. The abstract of this OA review:

Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease. This is largely due to the inability of these kinase inhibitors to kill leukemia stem cells (LSCs) responsible for disease relapse. This stem cell resistance is not associated with the BCR-ABL kinase domain mutations resistant to kinase inhibitors. Development of curative therapies for CML requires the identification of crucial molecular pathways responsible for the survival and self-renewal of LSCs. In this review, we will discuss our current understanding of these crucial molecular pathways in LSCs and the available therapeutic strategies for targeting these stem cells in CML.

Read the Rest...

Two Open Access reviews

§ October 11th, 2010 § Filed under Nano Medicine Comments Off on Two Open Access reviews

1) Cancer Stem Cells in Pancreatic Cancer by Qi Bao and 6 co-authors, including Karl-Walter Jauch and Christiane J Bruns, Cancers 2010(Aug 19); 2(3): 1629-41. [Full text PDF][Scribd entry][Part of the Special Issue Pancreatic Cancer]. Abstract:

Pancreatic cancer is an aggressive malignant solid tumor well-known by early metastasis, local invasion, resistance to standard chemo- and radiotherapy and poor prognosis. Increasing evidence indicates that pancreatic cancer is initiated and propagated by cancer stem cells (CSCs). Here we review the current research results regarding CSCs in pancreatic cancer and discuss the different markers identifying pancreatic CSCs. This review will focus on metastasis, microRNA regulation and anti-CSC therapy in pancreatic cancer.

2) The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology by Alberto M Martelli and 4 co-authors, including James A McCubrey, Cancers 2010(Aug 18); 2(3): 1576-96. [Part of the Special Issue Cancer Stem Cells].

Comment: Review #2 is the first paper that has been published in the special issue on Cancer Stem Cells. As of August 20, 17 more contributions to this special issue are planned. Review #1, although about CSCs, is a contribution to a separate special issue on Pancreatic Cancer.

Read the Rest...

Isolation and killing of candidate CML stem cells by antibody targeting

§ October 11th, 2010 § Filed under Nano Medicine Comments Off on Isolation and killing of candidate CML stem cells by antibody targeting

Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein by Marcus Järås and 10 co-authors, including Thoas Fioretos, Proc Natl Acad Sci USA 2010(Aug 30). OA article. [Epub ahead of print][PubMed citation]. Abstract:

Chronic myeloid leukemia (CML) is genetically characterized by the Philadelphia (Ph) chromosome, formed through a reciprocal translocation between chromosomes 9 and 22 and giving rise to the constitutively active tyrosine kinase P210 BCR/ABL1. Therapeutic strategies aiming for a cure of CML will require full eradication of Ph chromosome-positive (Ph(+)) CML stem cells. Here we used gene-expression profiling to identify IL-1 receptor accessory protein (IL1RAP) as up-regulated in CML CD34(+) cells and also in cord blood CD34(+) cells as a consequence of retroviral BCR/ABL1 expression. To test whether IL1RAP expression distinguishes normal (Ph(-)) and leukemic (Ph(+)) cells within the CML CD34(+)CD38(-) cell compartment, we established a unique protocol for conducting FISH on small numbers of sorted cells. By using this method, we sorted cells directly into drops on slides to investigate their Ph-chromosome status. Interestingly, we found that the CML CD34(+)CD38(-)IL1RAP(+) cells were Ph(+), whereas CML CD34(+)CD38(-)IL1RAP(-) cells were almost exclusively Ph(-). By performing long-term culture-initiating cell assays on the two cell populations, we found that Ph(+) and Ph(-) candidate CML stem cells could be prospectively separated. In addition, by generating an anti-IL1RAP antibody, we provide proof of concept that IL1RAP can be used as a target on CML CD34(+)CD38(-) cells to induce antibody-dependent cell-mediated cytotoxicity. This study thus identifies IL1RAP as a unique cell surface biomarker distinguishing Ph(+) from Ph(-) candidate CML stem cells and opens up a previously unexplored avenue for therapy of CML.

Read the Rest...

« Older Entries Newer Entries »



Page 93«..1020..92939495..»